ID   BLVRB_HUMAN             Reviewed;         206 AA.
AC   P30043; A6NKD8; B2R5C6; P32078; P53005; Q32LZ2;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 171.
DE   RecName: Full=Flavin reductase (NADPH);
DE            Short=FR;
DE            EC=1.5.1.30 {ECO:0000269|PubMed:10620517, ECO:0000269|PubMed:18241201};
DE   AltName: Full=Biliverdin reductase B;
DE            Short=BVR-B;
DE            EC=1.3.1.24 {ECO:0000269|PubMed:10620517, ECO:0000269|PubMed:18241201, ECO:0000269|PubMed:7929092};
DE   AltName: Full=Biliverdin-IX beta-reductase;
DE   AltName: Full=Green heme-binding protein;
DE            Short=GHBP;
DE   AltName: Full=NADPH-dependent diaphorase;
DE   AltName: Full=NADPH-flavin reductase;
DE            Short=FLR;
GN   Name=BLVRB; Synonyms=FLR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 2-34; 63-87 AND
RP   98-206.
RC   TISSUE=Erythrocyte, and Reticulocyte;
RX   PubMed=8117274; DOI=10.1006/bbrc.1994.1165;
RA   Chikuba K., Yubisui T., Shirabe K., Takeshita M.;
RT   "Cloning and nucleotide sequence of a cDNA of the human erythrocyte
RT   NADPH-flavin reductase.";
RL   Biochem. Biophys. Res. Commun. 198:1170-1176(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=8799475; DOI=10.1248/bpb.19.796;
RA   Komuro A., Tobe T., Hashimoto K., Nakano Y., Yamaguchi T.,
RA   Nakajima H., Tomita M.;
RT   "Molecular cloning and expression of human liver biliverdin-IXbeta
RT   reductase.";
RL   Biol. Pharm. Bull. 19:796-804(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLN-46.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-205.
RC   TISSUE=Liver;
RX   PubMed=8280170; DOI=10.1006/bbrc.1993.2649;
RA   Yamaguchi T., Komuro A., Nakano Y., Tomita M., Nakajima H.;
RT   "Complete amino acid sequence of biliverdin-IX beta reductase from
RT   human liver.";
RL   Biochem. Biophys. Res. Commun. 197:1518-1523(1993).
RN   [9]
RP   PROTEIN SEQUENCE OF 2-21, SUBUNIT, CATALYTIC ACTIVITY, SUBCELLULAR
RP   LOCATION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=7929092;
RA   Yamaguchi T., Komoda Y., Nakajima H.;
RT   "Biliverdin-IX alpha reductase and biliverdin-IX beta reductase from
RT   human liver. Purification and characterization.";
RL   J. Biol. Chem. 269:24343-24348(1994).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-11.
RC   TISSUE=Liver;
RX   PubMed=1286669; DOI=10.1002/elps.11501301201;
RA   Hochstrasser D.F., Frutiger S., Paquet N., Bairoch A., Ravier F.,
RA   Pasquali C., Sanchez J.-C., Tissot J.-D., Bjellqvist B., Vargas R.,
RA   Appel R.D., Hughes G.J.;
RT   "Human liver protein map: a reference database established by
RT   microsequencing and gel comparison.";
RL   Electrophoresis 13:992-1001(1992).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-11.
RC   TISSUE=Erythrocyte;
RX   PubMed=8313871; DOI=10.1002/elps.11501401183;
RA   Golaz O., Hughes G.J., Frutiger S., Paquet N., Bairoch A.,
RA   Pasquali C., Sanchez J.-C., Tissot J.-D., Appel R.D., Walzer C.,
RA   Balant L., Hochstrasser D.F.;
RT   "Plasma and red blood cell protein maps: update 1993.";
RL   Electrophoresis 14:1223-1231(1993).
RN   [12]
RP   PROTEIN SEQUENCE OF 40-92; 64-78; 106-124 AND 146-170, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [13]
RP   IDENTITY OF FR AND BVR-B.
RX   PubMed=8687377; DOI=10.1042/bj3160385;
RA   Shalloe F., Elliott G., Ennis O., Mantle T.J.;
RT   "Evidence that biliverdin-IX beta reductase and flavin reductase are
RT   identical.";
RL   Biochem. J. 316:385-387(1996).
RN   [14]
RP   FUNCTION, ENZYME REGULATION, CATALYTIC ACTIVITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10620517; DOI=10.1042/bj3450393;
RA   Cunningham O., Gore M.G., Mantle T.J.;
RT   "Initial-rate kinetics of the flavin reductase reaction catalysed by
RT   human biliverdin-IXbeta reductase (BVR-B).";
RL   Biochem. J. 345:393-399(2000).
RN   [15]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-153.
RX   PubMed=18241201; DOI=10.1042/BJ20071495;
RA   Smith L.J., Browne S., Mulholland A.J., Mantle T.J.;
RT   "Computational and experimental studies on the catalytic mechanism of
RT   biliverdin-IXbeta reductase.";
RL   Biochem. J. 411:475-484(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-82, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.15 ANGSTROMS) IN COMPLEXES WITH
RP   MESOBILIVERDIN; BILIVERDIN; FLAVIN MONONUCLEOTIDE; LUMICHROME AND
RP   NADP, AND SUBUNIT.
RX   PubMed=11224564; DOI=10.1038/84948;
RA   Pereira P.J., Macedo-Ribeiro S., Parraga A., Perez-Luque R.,
RA   Cunningham O., Darcy K., Mantle T.J., Coll M.;
RT   "Structure of human biliverdin IXbeta reductase, an early fetal
RT   bilirubin IXbeta producing enzyme.";
RL   Nat. Struct. Biol. 8:215-220(2001).
CC   -!- FUNCTION: Broad specificity oxidoreductase that catalyzes the
CC       NADPH-dependent reduction of a variety of flavins, such as
CC       riboflavin, FAD or FMN, biliverdins, methemoglobin and PQQ
CC       (pyrroloquinoline quinone). Contributes to heme catabolism and
CC       metabolizes linear tetrapyrroles. Can also reduce the complexed
CC       Fe(3+) iron to Fe(2+) in the presence of FMN and NADPH. In the
CC       liver, converts biliverdin to bilirubin.
CC       {ECO:0000269|PubMed:10620517}.
CC   -!- CATALYTIC ACTIVITY: Reduced riboflavin + NADP(+) = riboflavin +
CC       NADPH. {ECO:0000269|PubMed:10620517, ECO:0000269|PubMed:18241201}.
CC   -!- CATALYTIC ACTIVITY: Bilirubin + NAD(P)(+) = biliverdin + NAD(P)H.
CC       {ECO:0000269|PubMed:10620517, ECO:0000269|PubMed:18241201,
CC       ECO:0000269|PubMed:7929092}.
CC   -!- ENZYME REGULATION: Mesobiliverdin acts as competitve inhibitor for
CC       flavin reduction, indicating that flavin and tetrapyrrole
CC       substrates compete for the same site.
CC       {ECO:0000269|PubMed:10620517}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=36 uM for NADP {ECO:0000269|PubMed:10620517,
CC         ECO:0000269|PubMed:7929092};
CC         KM=5.6 mM for NADH {ECO:0000269|PubMed:10620517,
CC         ECO:0000269|PubMed:7929092};
CC         KM=0.3 uM for biliverdin IX-beta {ECO:0000269|PubMed:10620517,
CC         ECO:0000269|PubMed:7929092};
CC         KM=52 uM for FMN {ECO:0000269|PubMed:10620517,
CC         ECO:0000269|PubMed:7929092};
CC         KM=125 uM for FAD {ECO:0000269|PubMed:10620517,
CC         ECO:0000269|PubMed:7929092};
CC         KM=53 uM for riboflavin {ECO:0000269|PubMed:10620517,
CC         ECO:0000269|PubMed:7929092};
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:11224564,
CC       ECO:0000269|PubMed:7929092}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:7929092}.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in liver and
CC       erythrocytes. At lower levels in heart, lung, adrenal gland and
CC       cerebrum. {ECO:0000269|PubMed:7929092}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/blvrb/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D26308; BAA05370.1; -; mRNA.
DR   EMBL; D32143; BAA06874.1; -; mRNA.
DR   EMBL; AK312137; BAG35073.1; -; mRNA.
DR   EMBL; AY340485; AAP88933.1; -; Genomic_DNA.
DR   EMBL; AC010271; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471126; EAW56969.1; -; Genomic_DNA.
DR   EMBL; BC109371; AAI09372.1; -; mRNA.
DR   CCDS; CCDS33029.1; -.
DR   PIR; JC2070; JC2070.
DR   RefSeq; NP_000704.1; NM_000713.2.
DR   UniGene; Hs.515785; -.
DR   PDB; 1HDO; X-ray; 1.15 A; A=2-205.
DR   PDB; 1HE2; X-ray; 1.20 A; A=2-205.
DR   PDB; 1HE3; X-ray; 1.40 A; A=2-205.
DR   PDB; 1HE4; X-ray; 1.40 A; A=2-205.
DR   PDB; 1HE5; X-ray; 1.50 A; A=2-205.
DR   PDBsum; 1HDO; -.
DR   PDBsum; 1HE2; -.
DR   PDBsum; 1HE3; -.
DR   PDBsum; 1HE4; -.
DR   PDBsum; 1HE5; -.
DR   ProteinModelPortal; P30043; -.
DR   SMR; P30043; -.
DR   BioGrid; 107114; 12.
DR   IntAct; P30043; 6.
DR   MINT; MINT-5001335; -.
DR   STRING; 9606.ENSP00000263368; -.
DR   DrugBank; DB03461; 2'-Monophosphoadenosine 5'-Diphosphoribose.
DR   DrugBank; DB02073; Biliverdine Ix Alpha.
DR   DrugBank; DB04363; Mesobiliverdin Iv Alpha.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00140; Riboflavin.
DR   DrugBank; DB03247; Riboflavin Monophosphate.
DR   iPTMnet; P30043; -.
DR   PhosphoSitePlus; P30043; -.
DR   BioMuta; BLVRB; -.
DR   DMDM; 1706870; -.
DR   DOSAC-COBS-2DPAGE; P30043; -.
DR   REPRODUCTION-2DPAGE; IPI00783862; -.
DR   SWISS-2DPAGE; P30043; -.
DR   UCD-2DPAGE; P30043; -.
DR   EPD; P30043; -.
DR   PaxDb; P30043; -.
DR   PeptideAtlas; P30043; -.
DR   PRIDE; P30043; -.
DR   TopDownProteomics; P30043; -.
DR   Ensembl; ENST00000263368; ENSP00000263368; ENSG00000090013.
DR   GeneID; 645; -.
DR   KEGG; hsa:645; -.
DR   CTD; 645; -.
DR   DisGeNET; 645; -.
DR   GeneCards; BLVRB; -.
DR   HGNC; HGNC:1063; BLVRB.
DR   HPA; HPA041698; -.
DR   HPA; HPA041937; -.
DR   MIM; 600941; gene.
DR   neXtProt; NX_P30043; -.
DR   OpenTargets; ENSG00000090013; -.
DR   PharmGKB; PA25374; -.
DR   eggNOG; ENOG410IXV9; Eukaryota.
DR   eggNOG; ENOG4111JAS; LUCA.
DR   GeneTree; ENSGT00390000014810; -.
DR   HOGENOM; HOG000262432; -.
DR   HOVERGEN; HBG050695; -.
DR   InParanoid; P30043; -.
DR   KO; K05901; -.
DR   OMA; TDEYNGH; -.
DR   OrthoDB; EOG091G0PLW; -.
DR   PhylomeDB; P30043; -.
DR   TreeFam; TF324063; -.
DR   BRENDA; 1.3.1.24; 2681.
DR   BRENDA; 1.5.1.30; 2681.
DR   Reactome; R-HSA-189483; Heme degradation.
DR   EvolutionaryTrace; P30043; -.
DR   GenomeRNAi; 645; -.
DR   PRO; PR:P30043; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000090013; -.
DR   CleanEx; HS_BLVRB; -.
DR   ExpressionAtlas; P30043; baseline and differential.
DR   Genevisible; P30043; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043195; C:terminal bouton; IEA:Ensembl.
DR   GO; GO:0004074; F:biliverdin reductase activity; IDA:UniProtKB.
DR   GO; GO:0042602; F:riboflavin reductase (NADPH) activity; IDA:UniProtKB.
DR   GO; GO:0042167; P:heme catabolic process; IDA:UniProtKB.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   Pfam; PF13460; NAD_binding_10; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   NADP; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:1286669,
FT                                ECO:0000269|PubMed:7929092,
FT                                ECO:0000269|PubMed:8117274,
FT                                ECO:0000269|PubMed:8280170,
FT                                ECO:0000269|PubMed:8313871}.
FT   CHAIN         2    206       Flavin reductase (NADPH).
FT                                /FTId=PRO_0000064948.
FT   NP_BIND      10     15       NADP.
FT   NP_BIND      54     55       NADP.
FT   NP_BIND      75     78       NADP.
FT   BINDING      35     35       NADP.
FT   BINDING     132    132       NADP.
FT   BINDING     153    153       Substrate.
FT   BINDING     154    154       NADP; via amide nitrogen.
FT   MOD_RES      42     42       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      82     82       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT      46     46       R -> Q (in dbSNP:rs11547746).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_019168.
FT   MUTAGEN     153    153       H->A: Reduced affinity for biliverdin.
FT                                {ECO:0000269|PubMed:18241201}.
FT   CONFLICT     16     16       G -> C (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   STRAND        5     10       {ECO:0000244|PDB:1HDO}.
FT   HELIX        14     25       {ECO:0000244|PDB:1HDO}.
FT   STRAND       29     35       {ECO:0000244|PDB:1HDO}.
FT   HELIX        37     39       {ECO:0000244|PDB:1HDO}.
FT   STRAND       42     44       {ECO:0000244|PDB:1HDO}.
FT   STRAND       48     53       {ECO:0000244|PDB:1HDO}.
FT   HELIX        58     65       {ECO:0000244|PDB:1HDO}.
FT   STRAND       69     73       {ECO:0000244|PDB:1HDO}.
FT   HELIX        86    101       {ECO:0000244|PDB:1HDO}.
FT   STRAND      105    109       {ECO:0000244|PDB:1HDO}.
FT   HELIX       112    114       {ECO:0000244|PDB:1HDO}.
FT   HELIX       118    120       {ECO:0000244|PDB:1HE2}.
FT   HELIX       123    125       {ECO:0000244|PDB:1HDO}.
FT   HELIX       126    141       {ECO:0000244|PDB:1HDO}.
FT   STRAND      144    149       {ECO:0000244|PDB:1HDO}.
FT   STRAND      152    155       {ECO:0000244|PDB:1HDO}.
FT   STRAND      164    169       {ECO:0000244|PDB:1HDO}.
FT   STRAND      174    177       {ECO:0000244|PDB:1HDO}.
FT   HELIX       178    187       {ECO:0000244|PDB:1HDO}.
FT   HELIX       188    190       {ECO:0000244|PDB:1HE2}.
FT   TURN        193    196       {ECO:0000244|PDB:1HDO}.
FT   STRAND      198    202       {ECO:0000244|PDB:1HDO}.
SQ   SEQUENCE   206 AA;  22119 MW;  3057E6D69A9F9F9F CRC64;
     MAVKKIAIFG ATGQTGLTTL AQAVQAGYEV TVLVRDSSRL PSEGPRPAHV VVGDVLQAAD
     VDKTVAGQDA VIVLLGTRND LSPTTVMSEG ARNIVAAMKA HGVDKVVACT SAFLLWDPTK
     VPPRLQAVTD DHIRMHKVLR ESGLKYVAVM PPHIGDQPLT GAYTVTLDGR GPSRVISKHD
     LGHFMLRCLT TDEYDGHSTY PSHQYQ
//
